Association of Young Age with Bone Mineral Density Improvement with Denosumab Treatment in Patients with Osteoporosis

Introduction: Analysis of predictive factors for the improvement of bone mineral density (BMD) in response to osteoporosis treatment is critical. Several studies reported on the analysis of bone turnover markers as a predictive factor for the improvement of BMD; however, few studies reported on predictive factors other than bone turnover markers. Thus, this study aimed to analyze other predictive factors for distal radial BMD improvement in response to denosumab treatment among patients with osteoporosis.Methods: We evaluated 133 patients with osteoporosis over a 24 month period. All patients received denosumab (60 mg) subcutaneously every 6 months. The BMD of the distal radius was assessed in all patients and serum concentrations of PINP and TRACP5b determined.Results: Denosumab treatment resulted in a 3.3% increase, from baseline, in distal radius BMD at 24 months. The average BMD change at 24 months was not significantly changed in relation to gender or prevalent medication. The average BMD change at 24 months was negatively correlated with patient’s age. Almost all the points of PINP and TRACP5b were not correlated with BMD except TRACP5b value at 24 months.Conclusions: We found that improvement of bone mineral density with denosumab treatment for osteoporosis is associated with young age of the patients. We recommend denosumab treatment for younger patients with osteoporosis.